Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Currently
March ‘19 QMC receives $500K upfront licensing fee for Assam, India solar project,
April ‘19 QMC unveils industry first 100% cadmium free, RoHS compliant, quantum dot LCD display film with 95% Rec. 2020 color gamut coverage,
June ‘19 QMC announces $1Million equipment order for Assam India solar project,
July ‘19 QMC announces expansion of Assam India solar project in update,
August ‘19 QMC acquires Capstan Platform Inc. a leader in blockchain platform design to build QMC's anti-counterfeit product line. Jay Williams a long-time technology pioneer and architect joins QMC as Chief Technology Officer,
September ‘19 QMC establishes a business advisory board with deep experience and networks spanning supply chain, national security, government, technology, consumer goods, finance and more,
September ‘19 QMC announces anti-counterfeit focus with QDX Ledger Blockchain Platform and new hire John Hartigan as Chief Revenue Officer,
October ‘19 QMC releases update on our Assam, India licensee’s solar project with increased volume and revenue projected for 2021 due to expansion from the original 20,000 sq. ft facility to 75,000 sq. Ft.,
November ‘19 QMC provides vision and market opportunities for the QDX Ledger Anti-counterfeit Platform in live webinar,
January '20 letter of intent signed for $2M equity investment and Joint Venture to form Quantum Materials Vertical Technologies, LLC.
Same on buying shares, adding next week if share price stays or goes down. Our vaccine still is in the running in spite of lack of exposure.
With Covid-19 ARR has MBS which makes this very safe.
EOD action shorts covering and impatient outs.
Have a great day thanks for posting the India letter. :)
The company is fine, Its the exposure that is the problem and being on the OTC. Fortunately my other investments are cushioning. If a successful vaccine then every one in the world will come.
https://newsfilter.io/latest/fda-approvals
https://newsfilter.io/latest/coronavirus-news
The company is backed by FM GM the price is a gift.
Calm waters, QMC will prevail
Nice, calm waters prevail.
You may want to look at the I-Box yes a 5:2 dividend was paid to investors for GNBT and Future NGIO which has filed an S-1 and a Form 10 and will be trading on the NASDAQ in MAY.
Joe Moscato did not go to China however the deal is finalized. All info is in the I-Box which has been put together by myself.
Posting the same speculation does not make it a fact.
There is no April Fool with thousands dying of Covid-19
Bought a few yesterday, this decision does not effect anything outside of the US and could be overturned. Im sure they will contest this decision made by this judge.
Thanks for reaching out.
This post is informative as where MILV is currently. Looking forward to the status change which will help longs recover what has been lost in the broader market.
Tired of getting out my pruners and cutting back and selling securities for safer plays. Have a good chunk of $$ here
Learned something in the first sentence. Long Thanks Mike
Great Article added today under 5 https://seekingalpha.com/article/4335332-panic-for-mortgage-reits-investors-are-asking-tough-questions
Gee its holding at .02 vs everything else crashing.
Yep, No debt and hopefully more visibility soon besides the DD done by Eco and others.
Many invested here know each other, at least online. That core is a nice feeling that the DD done by Eco, Aqua, DX and others have merit.
Your points may have meaning about what happened the past however the share structure and the name change has happened. I hope that the CE comes off which will help others besides the core group who I trust.
We also talking about a stock trading at .0055. We're in volitle times due to Covid-19. I hope updates happen sooner than later.
The REIT seems safer longer term however in the new world of Covid-19 ??
With Covid-19 Raging This is a PERFECT TIME for NDT to Introduce their wellness drink. With no debt and shares under control this is looking great for the longs.
Is AMRN a Current Buy under 4?? REITS like NRZ seem undervalued I have a position.
Yikes, I had shares b4 FDA ??Approval?? Sold for a small profit back in December.
"Just saw Dr. Marc Siegel talk on FOX about Leronlimab" found this on CYDY's page by a few there. Obviously this is getting much airplay and attention.
I am invested in a Vaccine GNBT WHO listed, Leronllimab is more of a "treatment".
Investments in both treatment and vaccine companies. Cytodyn has a treatment for the most ill currently suffering from severe Pneumonia due to the Covid-19 an FDA Approval seems likely. All the stops are being pulled from my observation.
CYDY is a damn good company, there are others on the OTC worth looking at.
World Health Org Listing: PDF File Pg 3 Not all OTC's are the same as you claim https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
COVID-19:Generex/Epivax Vaccine 5M Chinese Funded/Trials Within 90 Days
NASDAQ May: NGIO/New Generex Diagnostic/S-1/Form 10 GNBT Spinoff
Why GNBT/NGIO/Epi-Vax has an Advantage in the Covid-19 Vaccine Race
NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has developed our proprietary, patented Ii-Key immune systemactivation technology that holds promise for stopping pandemic viral outbreaks like the current SARS-COV-2 coronavirus epidemic in China. NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone. The activity and safety of Ii Key peptide vaccines has been proven in Phase I and II clinical trials involving over 300 patients or volunteers, so new Ii-Key has been proven in Phase I
and II clinical trials involving over 300 patients or volunteers, so new Ii-Key vaccines should be able to proceed directly to human studies without significant pre-clinical toxicology testing. With human clinical data in hundreds of patients that demonstrate safety and immune system activation against infectious disease and tumor antigens, as well as preclinical in vitro and in vivo studies that prove the mechanism of T-Cell activation, the Ii-Key technology offers a rapid path to humanprotection from the SARS-COV-2 and COVID-19 epidemic.
NGIO is working with EpiVax to utilize their proprietary computational vaccinology algorithms and databases to guide the rapid development of Ii-Key peptide vaccines to protect against the spread of SARS-COV-2. EpiVax has developed a suite of online computational vaccinology tools
for the accelerated design of proteome-derived, epitope-driven vaccines. NGIO and EpiVax are generating new patents and intellectual
properties from this collaborative agreement.
Note: NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer.
https://investorshub.advfn.com/Generex-Biotechnology-Corp-GNBT-4711/
Hey doc bought in today, may add, along with Generex GNBT finding the Vaccine that works. The OTC companies may just come thru vs the big boys. Nice job on the I-Box here.
Pete Repeat Broken Record |
One of Many Subs
Generex Biotechnology Subsidiary Olaregen Therapeutics’ Wound Conforming Matrix, Excellagen®, Awarded Strategic Acquisition Centers (SAC) Biologic Blanket Purchase Agreement (BPA) Contract
http://www.globenewswire.com/news-release/2020/03/30/2008425/0/en/Generex-Biotechnology-Subsidiary-Olaregen-Therapeutics-Wound-Conforming-Matrix-Excellagen-Awarded-Strategic-Acquisition-Centers-SAC-Biologic-Blanket-Purchase-Agreement-BPA-Contract.html
Generex Participating on Expert Panel for Fierce Pharma & Fierce Healthcare Corona Virus Virtual Series
Dr. Eric von Hofe, PhD, Chief Scientific Officer of NuGenerex Immuno-Oncology to Speak on the Race to Develop a SARS-CoV-2 Vaccine Monday March 30, 2020 at 3 PM
http://www.globenewswire.com/news-release/2020/03/30/2008333/0/en/Generex-Participating-on-Expert-Panel-for-Fierce-Pharma-Fierce-Healthcare-Corona-Virus-Virtual-Series.html
I-Box Top is dialed in, all we need is a successful Vaccine.
Agreed you never know what all-other companies Big Small Penny Private Foreign have in this Covid-19 Epidemic and finding a treatment vaccine or a cure.
Hidden in the Covid-19 shuffle/Why GNBT/NGIO has an Advantage in the Covid-19 Vaccine Race/Besides 5M Contract from China/NGIO will have a NASDAQ Listing in May they entered a S-1 Form 10 NGIO Formerly Antigen Express
Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination
NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone.
Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination
------------------------------------------------------------------
NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has developed our proprietary, patented Ii-Key immune system
activation technology that holds promise for stopping pandemic viral outbreaks like the current SARS-COV-2 coronavirus epidemic in China. NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone. The activity and safety of Ii Key peptide vaccines has been proven in Phase I and II clinical trials involving over 300 patients or volunteers, so new Ii-Key has been proven in Phase I
and II clinical trials involving over 300 patients or volunteers, so new Ii-Key vaccines should be able to proceed directly to human studies without significant pre-clinical toxicology testing. With human clinical data in hundreds of patients that demonstrate safety and immune system activation against infectious disease and tumor antigens, as well as preclinical in vitro and in vivo studies that prove the mechanism of T-Cell activation, the Ii-Key technology offers a rapid path to humanprotection from the SARS-COV-2 and COVID-19 epidemic.
NGIO is working with EpiVax to utilize their proprietary computational vaccinology algorithms and databases to guide the rapid development of Ii-Key peptide vaccines to protect against the spread of SARS-COV-2. EpiVax has developed a suite of online computational vaccinology tools
for the accelerated design of proteome-derived, epitope-driven vaccines. NGIO and EpiVax are generating new patents and intellectual
properties from this collaborative agreement.
https://epivax.com/
See I-Box on this 50c Investment
Thank you Dew for letting me postthis
https://investorshub.advfn.com/Generex-Biotechnology-Corp-GNBT-4711/